Nuno Rui Paulino Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nuno Rui Paulino Pereira has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Joseph H. Schwab
Department of Orthopaedic Surgery, Orthopaedic Oncology Service, Massachusetts General Hospital-Harvard Medical School, Boston, Massachusetts
5 shared publicationsStein J. Janssen
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
4 shared publications- Stein Jasper Janssen
Department of Orthopedic Surgery and Sports Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
4 shared publications Francis J. Hornicek
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3 shared publications- Joseph H. Schwab
Massachusetts General Hospital
3 shared publications - Marco L. Ferrone
Department of Orthopaedic Surgery, Mass General Brigham, Harvard Medical School, Boston, MA, USA
3 shared publications
Latest Publications
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Orthopaedics
- Vol. 28, 134-139
Estimating survival and choosing treatment for spinal metastases: Do spine surgeons agree with each other?
- 1 November 2021
- Published by Elsevier in Journal of Orthopaedics
- Vol. 28, 134-139
Open AccessEstimating survival and choosing treatment for spinal metastases: Do spine surgeons agree with each other?
- 29 May 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (3) , 376-381
Physical function and pain intensity in patients with metastatic bone disease
Background: Patient reported outcome data in bone metastatic disease are scarce and it would be useful to have normative data and understand what patients are at risk for poor function and more pain.Objectives: We aimed to assess what factors are independently associated with physical function and pain intensity in patients with bone metastasis.Methods: We included data from 211 patients with bone metastasis who completed a survey (2014‐2016) including the PROMIS Physical Function Cancer and PROMIS Pain Intensity questionnaires.Results: Prostate (P < .001) and thyroid carcinoma (P = .007) were associated with better function and having other disabling conditions (P = 0.035) was associated with worse function. Prostate carcinoma (P = .001) and lymphoma (P = .007) were associated with less pain. There was a moderate correlation between pain and function (P < .001). Function was substantially worse as compared to a US reference population of patients with cancer (P < .001), whereas pain was slightly less compared to the US general population average (P < .001).Conclusions: Patients with bone metastasis have a poor physical function. Physical function and pain intensity depend on tumor histology, but also on potentially modifiable factors such as other disabling conditions.Level of Evidence: Level III, prognostic study.
- 29 May 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (3) , 376-381
Physical function and pain intensity in patients with metastatic bone disease
Background: Patient reported outcome data in bone metastatic disease are scarce and it would be useful to have normative data and understand what patients are at risk for poor function and more pain.Objectives: We aimed to assess what factors are independently associated with physical function and pain intensity in patients with bone metastasis.Methods: We included data from 211 patients with bone metastasis who completed a survey (2014‐2016) including the PROMIS Physical Function Cancer and PROMIS Pain Intensity questionnaires.Results: Prostate (P < .001) and thyroid carcinoma (P = .007) were associated with better function and having other disabling conditions (P = 0.035) was associated with worse function. Prostate carcinoma (P = .001) and lymphoma (P = .007) were associated with less pain. There was a moderate correlation between pain and function (P < .001). Function was substantially worse as compared to a US reference population of patients with cancer (P < .001), whereas pain was slightly less compared to the US general population average (P < .001).Conclusions: Patients with bone metastasis have a poor physical function. Physical function and pain intensity depend on tumor histology, but also on potentially modifiable factors such as other disabling conditions.Level of Evidence: Level III, prognostic study.
- Open Access
- 18 February 2019
- Published by SAGE Publications in Global Spine Journal
- Vol. 9 (7) , 743-753
Physical Function and Quality of Life After Resection of Mobile Spine Chondrosarcoma
Retrospective cohort study. (1) To assess patient-reported outcomes—physical function, pain, and quality of life—in patients who underwent resection of a mobile spine chondrosarcoma. (2) To assess complications (90 days), readmissions, reoperations, oncological outcomes, and neurologic status. Thirty-three patients with spinal conventional chondrosarcoma resection between 1984 and 2014 at one hospital were included. The primary outcome measures were—minimally 6 months after surgery—the EuroQol 5 Dimensions (EQ5D), PROMIS–Physical Function, PROMIS–Pain Intensity, and Oswestry (ODI) Disability Index, or Neck (NDI) Disability established in 14 out of 20 alive (70.0%) patients. Complications, readmission, reoperations, oncological outcomes, and neurological status were reported for the complete cohort of 33 patients. After spine chondrosarcoma resection, patients (n = 14) reported worse physical function (median 43, range 22-61, P = .026), worse quality of life (median EQ5D 0.70, range 0.04-1, P = .022), and comparable pain intensity (median 47, range 31-56, P = .362) when compared with US general population values. The median NDI/ODI was 25 (range 0-72) indicating mild to moderate disability. Patients undergoing reoperation had worse patient-reported outcomes than those who did not. Eighteen (55.5%) out of 33 patients suffered complications (90 days), 14 (42.4%) had unplanned readmission, and 13 (39.4%) underwent reoperation. Intralesional resection was associated with increased readmission, reoperation, and recurrence rate. Chondrosarcoma affects quality of life and physical function and its treatment frequently results in complications and reoperations. Our findings can be used to inform future patients about expected outcomes.
- 18 February 2019
- Published by SAGE Publications in Global Spine Journal
- Vol. 9 (7) , 743-753
Open AccessPhysical Function and Quality of Life After Resection of Mobile Spine Chondrosarcoma
Retrospective cohort study. (1) To assess patient-reported outcomes—physical function, pain, and quality of life—in patients who underwent resection of a mobile spine chondrosarcoma. (2) To assess complications (90 days), readmissions, reoperations, oncological outcomes, and neurologic status. Thirty-three patients with spinal conventional chondrosarcoma resection between 1984 and 2014 at one hospital were included. The primary outcome measures were—minimally 6 months after surgery—the EuroQol 5 Dimensions (EQ5D), PROMIS–Physical Function, PROMIS–Pain Intensity, and Oswestry (ODI) Disability Index, or Neck (NDI) Disability established in 14 out of 20 alive (70.0%) patients. Complications, readmission, reoperations, oncological outcomes, and neurological status were reported for the complete cohort of 33 patients. After spine chondrosarcoma resection, patients (n = 14) reported worse physical function (median 43, range 22-61, P = .026), worse quality of life (median EQ5D 0.70, range 0.04-1, P = .022), and comparable pain intensity (median 47, range 31-56, P = .362) when compared with US general population values. The median NDI/ODI was 25 (range 0-72) indicating mild to moderate disability. Patients undergoing reoperation had worse patient-reported outcomes than those who did not. Eighteen (55.5%) out of 33 patients suffered complications (90 days), 14 (42.4%) had unplanned readmission, and 13 (39.4%) underwent reoperation. Intralesional resection was associated with increased readmission, reoperation, and recurrence rate. Chondrosarcoma affects quality of life and physical function and its treatment frequently results in complications and reoperations. Our findings can be used to inform future patients about expected outcomes.
- 1 January 2019
- Published by Elsevier in The Spine Journal
- Vol. 19 (1) , 144-156
Complications and reoperations after surgery for 647 patients with spine metastatic disease
- 1 January 2019
- Published by Elsevier in The Spine Journal
- Vol. 19 (1) , 144-156
Complications and reoperations after surgery for 647 patients with spine metastatic disease
- 1 March 2018
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 23 (2) , 394-402
Predicting pathological fracture in femoral metastases using a clinical CT scan based algorithm: A case–control study
- 1 March 2018
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 23 (2) , 394-402
Predicting pathological fracture in femoral metastases using a clinical CT scan based algorithm: A case–control study
- 1 July 2017
- Published by Elsevier in The Spine Journal
- Vol. 17 (7) , 969-976
The prevalence of spinal epidural lipomatosis on magnetic resonance imaging
- 1 July 2017
- Published by Elsevier in The Spine Journal
- Vol. 17 (7) , 969-976
The prevalence of spinal epidural lipomatosis on magnetic resonance imaging
- 1 July 2017
- Published by Elsevier in The Spine Journal
- Vol. 17 (7) , 953-961
Most efficient questionnaires to measure quality of life, physical function, and pain in patients with metastatic spine disease: a cross-sectional prospective survey study
- 1 July 2017
- Published by Elsevier in The Spine Journal
- Vol. 17 (7) , 953-961
Most efficient questionnaires to measure quality of life, physical function, and pain in patients with metastatic spine disease: a cross-sectional prospective survey study
- 27 March 2017
- Published by Wiley in Journal of Surgical Oncology
- Vol. 115 (8) , 1019-1027
The SORG nomogram accurately predicts 3‐ and 12‐months survival for operable spine metastatic disease: External validation
Background and Objectives: Externally validate the SORG12 nomogram and SORG classic algorithm at estimating survival in patients with spine metastatic disease, and compare predictive accuracy with other survival algorithms.Methods: We received data from 100 patients who had surgery for spine metastatic disease at an external institution. Algorithms were accurate if the Area Under Curve (AUC) was >0.70, and we used Receiver Operating Characteristic (ROC) analysis to compare predictive accuracy with other algorithms.Results: The SORG nomogram accurately estimated 3‐months (AUC = 0.74) and 12‐months survival (AUC = 0.78); it did not accurately estimate 1‐month survival (AUC = 0.65). There was no difference in 1‐month survival accuracy between the SORG nomogram and SORG classic algorithm (P = 0.162). The SORG nomogram was best at predicting 3‐months survival, compared with the Tokuhashi score and SORG classic algorithm (P = 0.009). The SORG nomogram was best at predicting 12‐months survival, compared with the Tomita score, Ghori score, Bauer modified score, Tokuhashi score, and SORG classic algorithm (P = 0.033).Conclusions: The SORG nomogram accurately estimated 3‐ and 12‐months survival for operable spine metastatic disease, and is therefore, useful in clinical practice.
- 27 March 2017
- Published by Wiley in Journal of Surgical Oncology
- Vol. 115 (8) , 1019-1027
The SORG nomogram accurately predicts 3‐ and 12‐months survival for operable spine metastatic disease: External validation
Background and Objectives: Externally validate the SORG12 nomogram and SORG classic algorithm at estimating survival in patients with spine metastatic disease, and compare predictive accuracy with other survival algorithms.Methods: We received data from 100 patients who had surgery for spine metastatic disease at an external institution. Algorithms were accurate if the Area Under Curve (AUC) was >0.70, and we used Receiver Operating Characteristic (ROC) analysis to compare predictive accuracy with other algorithms.Results: The SORG nomogram accurately estimated 3‐months (AUC = 0.74) and 12‐months survival (AUC = 0.78); it did not accurately estimate 1‐month survival (AUC = 0.65). There was no difference in 1‐month survival accuracy between the SORG nomogram and SORG classic algorithm (P = 0.162). The SORG nomogram was best at predicting 3‐months survival, compared with the Tokuhashi score and SORG classic algorithm (P = 0.009). The SORG nomogram was best at predicting 12‐months survival, compared with the Tomita score, Ghori score, Bauer modified score, Tokuhashi score, and SORG classic algorithm (P = 0.033).Conclusions: The SORG nomogram accurately estimated 3‐ and 12‐months survival for operable spine metastatic disease, and is therefore, useful in clinical practice.
- 18 November 2016
- Published by Wiley in Journal of Surgical Oncology
- Vol. 114 (8) , 997-1003
Are perioperative allogeneic blood transfusions associated with 90‐days infection after operative treatment for bone metastases?
Background and Objectives: We assessed whether allogeneic blood transfusions were associated with infection—within 90 days—after surgery for bone metastatic disease. Furthermore, we assessed other risk factors associated with infection.Methods: We included 1,266 patients surgically treated for a bone metastasis at two hospitals between 2002 and 2013. Blood transfusions within 7 days before and after surgery were considered perioperative.Results: We found no independent association between exposure to blood transfusion and infection (odds ratio [OR] 1.02, 95% confidence interval [CI]: 0.76–1.37, P = 0.889), nor a dose–response relationship (OR 1.02, 95%CI: 0.98–1.07, P = 0.245). Older age (OR 1.01, 95%CI: 1.00–1.02, P = 0.035), a higher modified Charlson comorbidity index (OR 1.13, 95%CI: 1.05–1.22, P = 0.002), surgery to the axial skeleton (OR 1.89, 95%CI: 1.42–2.51, P < 0.001), and previous radiotherapy (OR 1.45, 95%CI 1.07–1.96, P = 0.015) were independently associated with infection.Conclusions: There was no association between allogeneic blood transfusion and infection. We found other risk factors that should be taken into consideration when deciding to operate. J. Surg. Oncol. 2016;114:997–1003.
- 18 November 2016
- Published by Wiley in Journal of Surgical Oncology
- Vol. 114 (8) , 997-1003
Are perioperative allogeneic blood transfusions associated with 90‐days infection after operative treatment for bone metastases?
Background and Objectives: We assessed whether allogeneic blood transfusions were associated with infection—within 90 days—after surgery for bone metastatic disease. Furthermore, we assessed other risk factors associated with infection.Methods: We included 1,266 patients surgically treated for a bone metastasis at two hospitals between 2002 and 2013. Blood transfusions within 7 days before and after surgery were considered perioperative.Results: We found no independent association between exposure to blood transfusion and infection (odds ratio [OR] 1.02, 95% confidence interval [CI]: 0.76–1.37, P = 0.889), nor a dose–response relationship (OR 1.02, 95%CI: 0.98–1.07, P = 0.245). Older age (OR 1.01, 95%CI: 1.00–1.02, P = 0.035), a higher modified Charlson comorbidity index (OR 1.13, 95%CI: 1.05–1.22, P = 0.002), surgery to the axial skeleton (OR 1.89, 95%CI: 1.42–2.51, P < 0.001), and previous radiotherapy (OR 1.45, 95%CI 1.07–1.96, P = 0.015) were independently associated with infection.Conclusions: There was no association between allogeneic blood transfusion and infection. We found other risk factors that should be taken into consideration when deciding to operate. J. Surg. Oncol. 2016;114:997–1003.
- 2 November 2016
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 98 (21) , 1767-1776
Development of a Prognostic Survival Algorithm for Patients with Metastatic Spine Disease
Current prognostication models for survival estimation in patients with metastatic spine disease lack accuracy. Identifying new risk factors could improve existing models. We assessed factors associated with survival in patients surgically treated for spine metastases, created a classic scoring algorithm, nomogram, and boosting algorithm, and tested the predictive accuracy of the three created algorithms at estimating survival. We included 649 patients from two tertiary care referral centers in this retrospective study (2002 to 2014). A multivariate Cox model was used to identify factors independently associated with survival. We created a classic scoring system, a nomogram, and a boosting (i.e., machine learning) algorithm and calculated their accuracy by receiver operating characteristic analysis. Older age (hazard ratio [HR], 1.01; p = 0.009), poor performance status (HR, 1.54; p = 0.001), primary cancer type (HR, 1.68; p < 0.001), >1 spine metastasis (HR, 1.32; p = 0.009), lung and/or liver metastasis (HR, 1.35; p = 0.005), brain metastasis (HR, 1.90; p < 0.001), any systemic therapy for cancer prior to a surgical procedure (e.g., chemotherapy, immunotherapy, hormone therapy) (HR, 1.65; p < 0.001), higher white blood-cell count (HR, 1.03; p = 0.002), and lower hemoglobin levels (HR, 0.92; p = 0.009) were independently associated with decreased survival. The boosting algorithm was best at predicting survival on the training data sets (p < 0.001); the nomogram was more reliable at estimating survival on the test data sets, with an accuracy of 0.75 (30 days), 0.73 (90 days), and 0.75 (365 days). We identified risk factors associated with survival that should be considered in prognostication. Performance of the boosting algorithm and nomogram were comparable on the testing data sets. However, the nomogram is easier to apply and therefore more useful to aid surgical decision-making. Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
- 2 November 2016
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 98 (21) , 1767-1776
Development of a Prognostic Survival Algorithm for Patients with Metastatic Spine Disease
Current prognostication models for survival estimation in patients with metastatic spine disease lack accuracy. Identifying new risk factors could improve existing models. We assessed factors associated with survival in patients surgically treated for spine metastases, created a classic scoring algorithm, nomogram, and boosting algorithm, and tested the predictive accuracy of the three created algorithms at estimating survival. We included 649 patients from two tertiary care referral centers in this retrospective study (2002 to 2014). A multivariate Cox model was used to identify factors independently associated with survival. We created a classic scoring system, a nomogram, and a boosting (i.e., machine learning) algorithm and calculated their accuracy by receiver operating characteristic analysis. Older age (hazard ratio [HR], 1.01; p = 0.009), poor performance status (HR, 1.54; p = 0.001), primary cancer type (HR, 1.68; p < 0.001), >1 spine metastasis (HR, 1.32; p = 0.009), lung and/or liver metastasis (HR, 1.35; p = 0.005), brain metastasis (HR, 1.90; p < 0.001), any systemic therapy for cancer prior to a surgical procedure (e.g., chemotherapy, immunotherapy, hormone therapy) (HR, 1.65; p < 0.001), higher white blood-cell count (HR, 1.03; p = 0.002), and lower hemoglobin levels (HR, 0.92; p = 0.009) were independently associated with decreased survival. The boosting algorithm was best at predicting survival on the training data sets (p < 0.001); the nomogram was more reliable at estimating survival on the test data sets, with an accuracy of 0.75 (30 days), 0.73 (90 days), and 0.75 (365 days). We identified risk factors associated with survival that should be considered in prognostication. Performance of the boosting algorithm and nomogram were comparable on the testing data sets. However, the nomogram is easier to apply and therefore more useful to aid surgical decision-making. Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.